Results 41 to 50 of about 484,321 (343)

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana, Angelica T. Mejia, Miriam R. Elman, Daniel Kamna, Olives Nguyen, Hailey Volk, Hongya Chen, Ahmad Masri   +7 more
doaj   +1 more source

Automated segmentation of left ventricular myocardium using cascading convolutional neural networks based on echocardiography

AIP Advances, 2021
Quickly and accurately segmenting the left ventricular (LV) myocardium from ultrasound images and measuring the thickness of the interventricular septum and LV wall play an important role in hypertrophic cardiomyopathy.
Shenghan Ren, Yongbing Wang, Rui Hu, Lei Zuo, Liwen Liu, Heng Zhao   +5 more
doaj   +1 more source

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown.
Milla E. Arabadjian, Maria C. Reuter, Alexandra Stepanovic, Mark V. Sherrid, Daniele Massera   +4 more
doaj   +1 more source

Increased baseline ECG R-R dispersion predicts improvement in systolic function after atrial fibrillation ablation. [PDF]

, 2019
BackgroundAtrial fibrillation (AF) is associated with left ventricular (LV) systolic dysfunction which may improve after AF ablation. We hypothesised that increased ventricular irregularity, as measured by R-R dispersion on the baseline ECG, would ...
Buch, Eric, Chandrashekhar, Y, Koene, Ryan J, Li, Jian-Ming, Mbai, Mackenzi, Seo, Young-Ji, Shivkumar, Kalyanam, Tholakanahalli, Venkatakrishna N   +7 more
core   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura, Kentaro Ueno, Takuro Nishikawa, Yoshihiro Takahashi, Koji Nakae, Yasuhiro Okamoto   +5 more
wiley   +1 more source

Two Hearts at Risk

JACC: Case Reports, 2020
Hypertrophic obstructive cardiomyopathy (HOCM) increases the risk for mother and fetus during pregnancy. Alcohol septal ablation (ASA) is an established procedure in nonpregnant patients with HOCM. In this report, we present a case of a 29-year-old woman
Weng-Tein Gi, MD, MSc, Ali Amr, MD, Farbod Sedaghat-Hamedani, MD, Elham Kayvanpour, MD, Isabell Mohr, BSc, Manuela Meder, MD, Omid Shirvani Samani, MD, Herbert Fluhr, MD, Hugo A. Katus, MD, Benjamin Meder, MD   +9 more
doaj   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai, Natalie Szpakowski, Albree Tower‐Rader, Barb Bittel, Agostina Fava, Susan Ospina, Bo Xu, Maran Thamilarasan, Amgad Mentias, Nicholas G. Smedira, Zoran B. Popovic   +10 more
doaj   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C. Alvarez, Woon Y. Wu, Maria C. Reuter, Martin S. Maron, Barry J. Maron, Ethan J. Rowin   +9 more
doaj   +1 more source